

## Special Issue

# New Treatments for Inflammatory and Neoplastic Skin Diseases

### Message from the Guest Editor

In the last 15 years, the advent of biologics has revolutionized the treatment of psoriasis. After the first anti-tnf-alfa drugs, biosimilars are also now available; the anti-interleukin groups (anti-IL-17 and anti-IL-23) are safe and effective treatments for most psoriatic patients, even those with difficult-to-treat body areas. Furthermore, the management of atopic dermatitis has changed thanks to dupilumab and, subsequently, tralokinumab as well as the inhibitors of Janus kinases. In the near future, many other drugs, both biologics and small molecules, will be marketed for several skin diseases, including vitiligo, alopecia areata, and hidradenitis suppurativa. In the field of dermatology, immunotherapy and targeted therapies are currently used for difficult-to-treat locally advanced basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and melanoma. Sharing experiences of these treatments will enhance the knowledge and confidence of dermatologists. For this Special Issue, we expect reviews and original research on new approaches to the diagnosis and management of skin tumors.

### Guest Editor

Dr. Gianluca Nazzaro

1. Department of Physiopathology and Transplantation, University of Milan, 20122 Milan, Italy
2. Dermatology Unit, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, 20122 Milan, Italy

### Deadline for manuscript submissions

closed (30 November 2024)



## Journal of Clinical Medicine

an Open Access Journal  
by MDPI

Impact Factor 2.9  
CiteScore 5.2  
Indexed in PubMed



[mdpi.com/si/186761](https://mdpi.com/si/186761)

*Journal of Clinical Medicine*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[jcm@mdpi.com](mailto:jcm@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[jcm](https://jcm)





# Journal of Clinical Medicine

---

an Open Access Journal  
by MDPI

---

Impact Factor 2.9  
CiteScore 5.2  
Indexed in PubMed



[mdpi.com/journal/  
jcm](https://mdpi.com/journal/jcm)



## About the Journal

### Message from the Editorial Board

There has been an explosion of gene and target based research and therapeutics in the multitude of fields that compose clinical medicine. The *Journal of Clinical Medicine's* (JCM) staff and editorial board are dedicated to providing cutting edge, timely, and peer-reviewed articles covering the diverse subspecialties of clinical medicine. The journal publishes concise, innovative, and exciting research articles as well as clinically significant articles and reviews that are pertinent to the myriad of disciplines within medicine. The articles published are relevant to both primary care physicians and specialists. The journal's full-texts are archived in PubMed Central and indexed in PubMed. Please consider submitting your manuscripts for publication to our journal and check us out on-line!

---

### Editors-in-Chief

Prof. Dr. Emmanuel Andr s

Internal Medicine Department, University Hospital Strasbourg, 67081  
Strasbourg, France

Prof. Dr. Kent Doi

Department of Emergency and Critical Care Medicine, The University of  
Tokyo, Tokyo, Japan

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1  
(General Medicine)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.7 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the first half of 2025).